<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Pharmacology</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\16.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Pharmacology <a name='15:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	<p>
<img src="./Pharmacology/pasted_image.png"><img src="./Pharmacology/pasted_image001.png"><img src="./Pharmacology/pasted_image002.png">
</p>

<h1>1.OVERVIEW</h1>

<p>
→ immunomediated disease<br>
<ul style='padding-left: 30pt'>
<li>rheumatoid arthritis</li>
</ul>
→ WBC view the synovium (tissue in the cartilage of the bone)<br>
<ul style='padding-left: 210pt'>
<li>as nonself and initiate an inflammatory attack.</li>
</ul>
→ WBC activation <br>
<ul style='padding-left: 30pt'>
<li>stimulation of T-lymphocytes </li>
<li>recruit and activate monocytes and macrophages.</li>
<li>these cells [T] secrete pro-inflammatory cytokines </li>
</ul>
<div style='padding-left: 90pt'>
— tumor necrosis factor (TNF)-α +  — Interleukin (IL)-1         → into synovial cavity 
</div>
1.Increased cellular infiltration into the endothelium due to release of histamines / kinins / vasodilatory prostagladins<br>
2.increased production of C-creative by hepatocytes<br>
3.increased production and release of proteolytic enzymes (collagenases &amp; metalloproteinases)<br>
<ul style='padding-left: 30pt'>
<li>by chondrocytes (cells that maintain cartilage)</li>
<li>leading to degradation of cartilage</li>
</ul>
4.increased osteoclast activity (regulate bone breakdown)<br>
<ul style='padding-left: 30pt'>
<li>resulting in focal bone erosions and bone demineralization </li>
</ul>
5.systemic manifastation in which organs such as the heart lungs and liver are aded.<br>
→ B-lymphocytes also invovled an will produce rheumatoid factor<br>
<ul style='padding-left: 30pt'>
<li>and other antibodies which will maintain inflammaiton.</li>
</ul>
→ these defensive reactions<br>
<ul style='padding-left: 30pt'>
<li>progressive tissue injury </li>
<li>joint damage and erosions</li>
<li>functional disability </li>
<li>signifignant pain</li>
<li>reduction in quality of life.</li>
</ul>
→ Pharmacotherapy:<br>
<ul style='padding-left: 30pt'>
<li>anti-inflammatory</li>
<li>immunosupressive agents </li>
</ul>
→  that will modulate/reduce inflammataory process <br>
<ul style='padding-left: 30pt'>
<li>reducing inflammation and pain</li>
<li>halting (or at least slowing)</li>
<li>the progression of the disease.</li>
</ul>
→ NSAID's + celecoxib(COX-2-inhibitor) + acetaminophen + DMARDs (Disease-modifying-antirheumatic drugs)
</p>

<h1>2.DISEASE-MODIFYING ANTIRHEUMATIC AGENTS (DMARDs)</h1>

<p>
→ DMARD's used in the treatment of RA<br>
<ul style='padding-left: 30pt'>
<li>slow the course of the disease</li>
<li>induce remission</li>
<li>prevent further destruction of the join/tissues</li>
</ul>
→ Initiation of therapy with DMARD's within 3 months of diagnosis<br>
<div style='padding-left: 90pt'>
(in addition to NSAIDs,low dose,corticosteroids,physical therapy,occupational therapy)
</div>
<ul style='padding-left: 30pt'>
<li>help repidly to help stop the progression of the disease at the earlier stages</li>
</ul>
</p>
<h1>2.1 Choice of drug</h1>

<p>
→ NO one of DMARD's is effacious and safe → trials<br>
→ <i>Methotrexate or hydrochloroquine</i><br>
<ul style='padding-left: 30pt'>
<li>effacious</li>
<li>well tolarated</li>
<li>well known side effects profiles</li>
</ul>
→ Indaquate repsonse to traditional agents mentioned before<br>
<ul style='padding-left: 30pt'>
<li><i>Leflunomide</i></li>
<li>Anakinra</li>
<li>TNF inhibitors</li>
</ul>
— <i>Adalimumba — Etanercept — Golimumab — Cetrolizumab — Inflixmab</i><br>
→ Combination therapies are both safe and efficacious  (e.g. <i> </i>methotrexate + TNF inhibitor //or other combination)<br>
<ul style='padding-left: 30pt'>
<li>treatment with <i>Rituximab or abatacept </i>may be tried.</li>
</ul>
→ Most of these agents are contraindicated for use in pregnant women.
</p>

<h1>3.METHOTREXATE</h1>

<p>
→ synthetic antimetabolite<br>
→ used alone or in combination <br>
→ slow the appearence of new erosions within 3 to 6 weeks<br>
→ it is an immunosupressant<br>
<ul style='padding-left: 30pt'>
<li>effectiveness in autoimune disease [in higher doses]</li>
</ul>
→ most common side effects<br>
<ul style='padding-left: 30pt'>
<li>mucosal ulceration</li>
<li>nausea                 → common toxicities</li>
<li>leukopenia/anemia</li>
<li>GI ulceration and alopeia due to inhibiting cellular profilation</li>
<li>progressive related hepatotoxicity [in the form of enzyme elevation]</li>
<li>can be reduced by the use of —  <i>leucovorin</i> 24 —  hours after each weekly dose or daily folic acid</li>
</ul>
<ul>
<li>may decrease the methotrexate efficacy about 10%</li>
</ul>
→ CONTRAINDICATED : in pregnancy.
</p>

<h1>3.1Mechanism of action</h1>

<p>
→ inhibition of AICAR (aminoimidazolecarboxamide ribonucleotide tranfomylase) + thymidylate synthase<br>
<ul style='padding-left: 30pt'>
<li>which accumulates intracelluary</li>
<li>competatively inhibits AMP deaminase → accumulation of AMP</li>
<li>then AMP → extracellularly adenosine [ a potent inhibitor of inflammation] → disfunction of neutriphilis,macrophages,dentric cells and lymphocytes</li>
</ul>
→ secondary  effects<br>
<ul style='padding-left: 30pt'>
<li>polymorphonuclear chemotaxis</li>
<li>lymphocyte/macrophages function</li>
<li>stimulates apoptosis in immune-inflammataory cells</li>
<li>inhibition of proinflammataory cytokines linked to rheumatoid synovitis.</li>
</ul>
</p>

<h1>4.LEFLUNOMIDE</h1>

<p>
→ non-biologic/immunomodulatory agent<br>
→ used as monotherapy / combination [with methotrexate]			
</p>

<h1>4.1Mechanism of Action</h1>

<p>
→ rapid converstion <br>
<ul style='padding-left: 30pt'>
<li>intestine</li>
<li>plasma  			→ to it's active metabolite</li>
</ul>
→ arrest cells in the G1 phase of cell growht<br>
→ inhibit T-cells profilation + production of autoantibodies by B cells<br>
→ Secondary effects may be <br>
<ul style='padding-left: 30pt'>
<li>increase of interleukin-10 receptor mRNA</li>
<li>decrease intereleukin-8 type A receptor mRNA</li>
<li>decrease TNF-α-dependent nuclear factor</li>
</ul>
</p>

<h1>4.2Pharmacokinetics</h1>

<p>
→ completely absorbed <br>
→ plasma half-life of 19 days<br>
→ <i>cholestyramine </i>can enchance leflunomide excrection and increase tolta clearence by 50%
</p>

<h1>4.3Indicaiton</h1>

<p>
→ is effective as methotrexate<br>
→ rehumatoid arthritis<br>
→ inhibition of body damage<br>
→ reduce pain
</p>

<h1>4.4Adverse Effects</h1>

<p>
→ diarrhea<br>
→ elevation in liver enzymes<br>
<ul style='padding-left: 30pt'>
<li>can be reduced by decreasing the dose</li>
</ul>
→ mild alopecia<br>
→ weigh gain<br>
→ increase blood pressure<br>
→ CONTRAINDICATED : pregnancy
</p>

<h1>5.CHLOROQUINE &amp; HYDROXYCHLOROQUINE</h1>

<p>
→ non-biological <br>
→ also used in the treatment of malaria<br>
→ early, mild RA [often combined with <i>methrotrexate]</i>
</p>

<h1>5.1Mechanism of action</h1>

<p>
→ unclear<br>
→ suppression of T-lymphocytes [in response to mitogens]<br>
→ decrease leukocyte chemotaxis<br>
→ stabilization of lysosomal enzymes<br>
→ inhibition of DNA/RNA synthesis<br>
→ trapping of free radicals
</p>

<h1>5.2Pharmacokinetics</h1>

<p>
→ rapidly abosrbed<br>
→ 50% protein bound in plasma<br>
→ extensively tissue-bound<br>
<ul style='padding-left: 30pt'>
<li>particularly in melanin-containing tissues such as the eyes</li>
</ul>
→ blood elimination half life up to 45 days
</p>

<h1>5.3 Indiacation</h1>

<p>
→ they are not considered very effective DMARDS<br>
→ dose-loading may increase the rate of response<br>
→ although improve symptoms there is no evidence that these compounds alter bony damage<br>
→ dosage: 6.4 mg/kg/d → hydroxychloroquine<br>
<div style='padding-left: 90pt'>
200mg/kg/d → chloroquine
</div>
→ 3-6 monhts to obtain a response
</p>

<h1>5.4 Adverse effects</h1>

<p>
→ ocular toxicity may occur at dosage :<br>
<ul style='padding-left: 30pt'>
<li>greater than 250mg/d for chloroquine</li>
<li>greater than 6.4mg/kg/d for hydroxychloroquine</li>
</ul>
→ nause , dyspepsia , vomiting , abdominal , pain , rashes , nightmares.
</p>

<h1>6.SULFASALAZINE</h1>

<p>
→ synthetic DMARD<br>
→ metabolized to sulfapyridine[active moeity] and 5-aminosalicylic acid.<br>
→ early,mild RA in combination with hydroxychloroquine and methotrexate<br>
→ 10-20% of orally admin. is absorbed<br>
→ half-life 6-17 hours<br>
→ 2-3g/d<br>
→ onest of activity is 1 to 3 monhts<br>
→ 30% of patients discontinioun therapy because of toxicity <br>
→ nause , vomiting , headache , rash.<br>
→ associated with leukopenia 
</p>

<h1>7.AZATHIOPRINE</h1>

<p>
→ immunosupressive agent<br>
<ul style='padding-left: 30pt'>
<li>orally </li>
<li>parenteraly </li>
</ul>
→ chemical analog of the endogenous purines , adenine , guanine  and hypoxanthine <br>
→ metabolized to <i>6-mercaptopurine </i> by the liver<br>
→ combined with aspirin , NSAIDs , low dose corticosteroids in the treatment of RA<br>
→ dosage : 2 mg/kg/d<br>
→ low or absent thiopurine S-methyltranferase acitvity  [ dose adjustment is recommended]<br>
→ psoriatric arthritis, reactive arthritis and more<br>
→ patinets treated with "alkylating agent" — <i>cyclophosphamide — chlorambucil — melphalan</i><br>
<ul style='padding-left: 30pt'>
<li>may prohibit risk of neoplasia</li>
<li>GI distrurbances </li>
</ul>
→ avoid azothioprine during pregnancy or breast-feeding 
</p>

<h1>8.CYCLOPHOSPHAMIDE</h1>

<p>
→ bifunctional alkylating agent 	( related to mechlorethamine ) [synthetic DMARDS]<br>
→ <br>
→ produce cytotoxic effects<br>
<ul style='padding-left: 30pt'>
<li>B and T ceels </li>
<li>selectively suppress B-lymphocytes activity.</li>
</ul>
→ orally dosage : 2mg/kg/d<br>
→ decrease immunoglobulin secretion<br>
→ in RA<br>
<ul style='padding-left: 30pt'>
<li>modulates the immune response</li>
</ul>
→ drug is cytotoic to many tissues<br>
→ myelosuppressive effect<br>
→ teratogenic <br>
→ GI distrubrances , alopecia , infertility
</p>

<h1>9.GLUCOCORTIDCOIDS</h1>

<p>
→ potent anti-infalammatory agents<br>
<ul style='padding-left: 30pt'>
<li>bridge the time until DMARDS are effective.</li>
<li>dose up to 10mg of <i>presidone.</i></li>
</ul>
</p>
<h1>BIOLOGIC THERAPIES IN RHEUMATAOID ARTHRITIS</h1>

<p>
→ intereleukin -1 and TNF-a<br>
<ul style='padding-left: 30pt'>
<li>pro inflammatory cytokines involed in the pathogenesisi of RA</li>
<li>stimulate synovial cells to profilate and synthesize collagenase</li>
<li>therby degrating cartilage,stimulating bone resorption and inhibiting proteoglycan synthesis</li>
</ul>
→ TNF-inhibitors <br>
<ul style='padding-left: 30pt'>
<li><i>Etanercept,Adalimumab,Infliximab,Golimumab,Cetrolizumab	</i></li>
<li>have shown to — decrease signs and symptoms of RA</li>
<li>reduce progression of structual damage,</li>
<li>improve physical function</li>
</ul>
→ 2-weeks of therapy<br>
→ if not respond to TNF an other one can be used <br>
<ul style='padding-left: 30pt'>
<li>or introduction of methotrexate</li>
</ul>
→ increased risk of infenction (turbeculosis/sepsis)<br>
→ fuglan opportunistic infenctions<br>
→ cautiously in those with heart failure
</p>

<h1>10.ETANERCEPT</h1>

<p>
→ genetically engineered<br>
→ soluble<br>
→ recombinant<br>
→ fully human receptor fusion protein that bind to TNF-a<br>
<ul style='padding-left: 30pt'>
<li>blocking its interaction with cell surface</li>
</ul>
→ used in moderate/severe RA<br>
<ul style='padding-left: 30pt'>
<li>polyarticular-course juvenile RA, psoriatic arthritis  , ankylosing spondylits, psoriasis</li>
</ul>
→ is more effective in combo with methotrexate<br>
<ul style='padding-left: 30pt'>
<li>retarding disease progress</li>
<li>improve function</li>
<li>achieving remission</li>
</ul>
→ After discontinuation of etanercept , the symptoms of RA generally return within a month
</p>

<h1>10.1Pharmacokinetics</h1>

<p>
→ subcutaneusly <br>
<ul style='padding-left: 30pt'>
<li>twice a week</li>
</ul>
→ max serum cocnc : 72hrs<br>
→ half-life : 115 hours
</p>

<h1>10.2Adverse Effects</h1>

<p>
→ well tolerated<br>
→ no toxicities or antibodies reproted<br>
→ can produce local inflammation at the site of infenction.
</p>

<h1>11.INFLIXIMAB</h1>

<p>
→ chimeric immunoglobulin Gk monoclonal antibody composed of human and murine regions<br>
→ binds specifically to human TNF-a → inhibits binding with its receptor<br>
→ in combination with methotrexate<br>
<ul style='padding-left: 30pt'>
<li>not used as monotherapy because of the development of antibodies  [ → reduction in efficacy]</li>
</ul>
</p>

<h1>11.1Pharmacokientics</h1>

<p>
→ infused IV over at least 2 hours<br>
→ half life : 9.5 days<br>
→ metabolism and elimination have not been described
</p>

<h1>11.2Adverse Effect</h1>

<p>
→ infusion site reactios<br>
<ul style='padding-left: 30pt'>
<li>fever chills , pruritus , urticaria , </li>
</ul>
→ infections leading to pneumonia<br>
→ leukopenia, neutropenia , thrombocytopenia , pancytopenia.
</p>

<h1>12.ADALIMUMAB</h1>

<p>
→ recombinant monoclonal antibody[IgG1] that binds to TNF-a <br>
<ul style='padding-left: 30pt'>
<li>intefering with endogenous TNF-a activity by blocking its binding to the surface receptors</li>
</ul>
→ reduction in the conc. of MMP-1(collagensase)<br>
<div style='padding-left: 210pt'>
MMP-3(stromelysin-1)<br>
C-creative proteins
</div>
→ moderate/severe RA<br>
→ monotherapy or in combination with methotrexate<br>
→ subcutaneously with half life of 10-20 days<br>
→ usual dosage for RA: 40mg every other weeks<br>
→ clearence is decreased by more than 40% in the presence of methotrexate<br>
→ it's also indicated for — psoriatic arthritis, ankylosing spondylitis , Crohn disease
</p>

<h1>12.1Pharmacokinetics</h1>

<p>
→ admin subcutaneusly weekly or every other week<br>
→ average absolute bioavailability is 64% and conc. in the synovial fluid may reach 31/96% of serum conc.<br>
→ headache, nausea, agranulocytosis , rash , increased risk of infenction.
</p>

<h1>12.2 Adverse effects</h1>

<p>
→ headache , nausea , agranulocytosis , rash , reaction in the site of injenction , increased risk of infention
</p>

<h1>13.GOLIMUMAB</h1>

<p>
→ neutralize the biological activity of TNF-α<br>
<ul style='padding-left: 30pt'>
<li>by binding to it and blocking its interaction with cell surface</li>
<li>bind to both soluble and the transmembrane bioactive forms of human TNF-α,</li>
<li>significant reduction in pro-inflammatory + autoimmune responses is observed.</li>
</ul>
</p>

<h1>13.1Pharmacokinetics</h1>

<p>
→ subcutaneously once a month  	(50mg)<br>
<ul style='padding-left: 30pt'>
<li>in combination with methotrexate or other nonbiologic DMARDs</li>
</ul>
→ half-life<br>
<ul style='padding-left: 30pt'>
<li>14 days</li>
</ul>
</p>

<h1>13.2Adverse effects</h1>

<p>
→ may increase hepatic enzymes<br>
→ may increase the risk of malignancies and serious infenctions<br>
<ul style='padding-left: 30pt'>
<li>turbeculosis</li>
<li>opportunistic infenction</li>
</ul>
→ injection site reactions <br>
<ul style='padding-left: 30pt'>
<li>erythema </li>
<li>itching </li>
<li>burning</li>
</ul>
</p>

<h1>14.CERTOLIZUMAB PEGOL</h1>

<p>
→ UNIQUe TNF-a blocker<br>
<ul style='padding-left: 30pt'>
<li>contains Fab fragment of a humanized antibody </li>
<li>potent neutralizer of TNF-a biological actions.</li>
</ul>
→ half-lifef 14 days<br>
→ clearence is decreased with decreasing body weight<br>
→ dosage : 400mg initially and at weeks 2 and 4.
</p>

<br>
<br>

<p>
→ combined with polyethylene glycol<br>
<ul style='padding-left: 30pt'>
<li>admin. every 2 weeks in combination with methotrexate</li>
<li>adr → similar to other TNF inhibitors.</li>
</ul>
</p>

<h1>15.ANAKINRA</h1>

<p>
→ IL-1 induced by inflammatory stimuli and mediates a variety of immunologic responses<br>
<ul style='padding-left: 30pt'>
<li>degradation of cartilage and stimulation of bone resorption</li>
</ul>
→ IL-1 receptor antagonist<br>
<ul style='padding-left: 30pt'>
<li>because it binds to  IL-1 receptor thus preventing actions of IL-1</li>
</ul>
→ modest reduction in the signs and symptoms of moderately to severely active RA in adult patients who have failed one or more DMARDs<br>
→ used alone or in combination with DMARDs [or TNF-inhibitors]<br>
→ monitoring in the site of infenction <br>
→ associated with neutropenia<br>
→ subcutaneously once a day if renal function is  normal<br>
<ul style='padding-left: 30pt'>
<li>every other day in those to moderate to severe renal impairment</li>
</ul>
</p>

<h1>16.ABATACEPT</h1>

<p>
→ T-lymphocytes needs two interaction to become active<br>
<ol style='padding-left: 30pt' type="1" start="1">
<li>antigen presenting cell (macrophages or B cells ) must interact with the receptor on the T-cell</li>
<li>proteins on the antigen-presenting interact with unit of protein on the T-cells.
<ul>
<li>resulting is activating T-lymphocytes responsible of inflammatmion in RA</li>
</ul></li>
</ol>
→ <i>Abatacept </i> is <br>
<ul style='padding-left: 30pt'>
<li>soluble recombinant fusion protein → preventing full T-cell activation</li>
</ul>
→ indicated for reducing signs and symptoms,<br>
<ul style='padding-left: 30pt'>
<li>slowing the progression of structual damage </li>
<li>improving physical function in adult patients with moderate to severe RA</li>
</ul>
<ul>
<li>patients tried and failed to the treatment with DMARDs/methotrexate/TNF-inhibitors/anakinra</li>
</ul>
</p>

<h1>16.1Pharmacokinetics</h1>

<p>
→ dosagea is based upon weight <br>
<ul style='padding-left: 30pt'>
<li>multiple dosage 10mg/kg is 13 days (range , 8-25 days)</li>
</ul>
</p>

<h1>16.2Adverse effects</h1>

<p>
→ headache , upper respiratory infenctions, nashopharyngitis , nausea
</p>

<h1>17.RITUXIMAB</h1>

<p>
→ B-lymphocytes are derived from the bone marrow and are necessary for efficient immune repsonse.<br>
<ul style='padding-left: 30pt'>
<li>in RA B-cells perpetuate the inflammatory process in the synovium</li>
</ul>
<ol type="1" start="1">
<li>activating T lymphocytes</li>
<li>producing autoantibodies and rheumatoid factor</li>
<li>producing pro-inflammatory cytokines (TNF-a and IL-a)</li>
</ol>
→ genetically engineered chimeric murine/human monoclonal antibody<br>
<ul style='padding-left: 30pt'>
<li>directed against CD20 antigen found on the surface of normal and indicated in combination with methotrexate.</li>
</ul>
→ reduce signs and symptoms of moderate to severe RA
</p>

<h1>17.1Pharmacokientics</h1>

<p>
→ admin. as two 1000mg IV infunsion separted by 2 weeks<br>
→ reduce severity of infunsion reactions <br>
<ul style='padding-left: 30pt'>
<li><i>methylprenisolone </i> at 100mg IV</li>
<li>equivalent admin. 30 minutes prior of each infunsion</li>
</ul>
</p>

<h1>17.2Adverse Effects</h1>

<p>
→ urticaria , hypotension , angioedema <br>
<ul style='padding-left: 30pt'>
<li>after the first infunsion</li>
</ul>
→ 
</p>

<p>
<img src="./Pharmacology/pasted_image004.png"><img src="./Pharmacology/pasted_image005.png">
</p>

	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>44.6kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>78.5kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>81.1kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>64.2kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>64.2kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image005.png'>pasted_image005.png</a></td><td>&nbsp;</td><td>92.8kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
